December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Aakash Desai: The next frontier in immunotherapy Oral immune checkpoint inhibitors
Dec 11, 2024, 14:33

Aakash Desai: The next frontier in immunotherapy Oral immune checkpoint inhibitors

Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:

“The next frontier in immunotherapy?

Oral immune checkpoint inhibitors (ICIs).

Early results from phase I trials of two oral PD-L1 inhibitors—ABSK043 and BPI-371153—show promising antitumor activity and manageable safety profiles in solid tumors, including NSCLC and MSI-high cancers.

Highlights:
• ABSK043: ORR of 19.6%, increasing to 41.7% in NSCLC with PD-L1 TPS ≥50%.
• BPI-371153: ORR of 23.5%, including a complete response in high PD-L1/TMB cases.
• Safety: No dose-limiting toxicities or peripheral neuropathy  in either trial.
• Mechanism: Both agents dimerise PD-L1, inducing receptor down-regulation and immune activation.

Oral ICIs offer tangible benefits over antibodies: cost efficiency, better tumor penetration, and patient convenience.

While further studies are needed, these agents could redefine how we approach immunotherapy if efficacy aligns with antibody-based ICIs.

Exciting times for oncology research.”

More posts featuring Aakash Desai.